Specialty chemicals major Epigral Ltd aims to grow at an annual growth rate of 20 per cent and is poised to more than double its revenue by FY2028, a top company official said on Saturday. Sustained demand for derivative and specialty products as well as doubling of production capacity will act as key catalysts for the overall revenue growth, Epigral's Chairman and Managing Director, Maulik Patel said in a statement. The company's consolidated revenue for 2023-24 stood at Rs 1936 crore. Epigral reported a little over 37 per cent jump in consolidated revenue to Rs 1,934.31 crore in the first nine months of 2024-25 compared to Rs 1,409.55 crore in the year-ago period, according to exchange filings. Derivatives & specialty business contributed 54 per cent to the topline. As per a research report by Sunidhi, Epigral's revenue is expected to be over Rs 3,500 crore by FY27. Another research firm Emkay in its report states that it expects revenue to be Rs 3,800 crore by FY27 with an ...